Figure 2.
Teduglutide treatment leads to improved survival and reduced histological scores in mice with acute SR-GVHD. (A) Percentage survival of C57BL/6 allo-HCT mice treated with teduglutide or vehicle (n = 17 per group). Mice were treated with teduglutide or vehicle from day −3 until day +3 unless differently specified. Results are derived from 3 independent experiments. P value was calculated using the Mantel-Cox test. (B) GVHD histopathological scores from target organs of allo-HCT C57BL/6 animals on day 10, mice were treated with teduglutide or vehicle (n = 7 per group). Results are derived from 1 experiment. The P values were calculated using a 2-sided Mann-Whitney U test. (C) Percentage survival of allo-HCT BALB/c mice treated with teduglutide or vehicle (n = 12 per group). Results are derived from 2 independent experiments. P value was calculated using the Mantel-Cox test. (D) GVHD histopathological scores from small and large intestine and liver from allo-HCT BALB/c mice on day 10, animals were treated with teduglutide or vehicle (n = 8 per group). Results are derived from 2 independent experiments. The P values were calculated using a 2-sided Mann-Whitney U test. (E) Percentage survival of allo-HCT BALB/c mice treated with vehicle or teduglutide from day −3 to day 3 + prednisolone from day 4 to day 13 (n = 10 per group). Data are derived from 2 independent experiments. P value was calculated using the Mantel-Cox test. (F) Histological GVHD scores from BALB/c mice on day 10, treated as the schedule above described with teduglutide + prednisolone or vehicle + prednisolone (n = 9 per group). Data are derived from 2 independent experiments. The P values were calculated using a 2-sided Mann-Whitney U test. (G) Percentage survival of syn-HCT BALB/c mice treated with teduglutide or vehicle (n = 5 per group). Results are derived from 1 experiment. P value was calculated using the Mantel-Cox test. (H) Relative Cldn4 gene expression in the small intestine of allo-HCT BALB/c mice on day 5, treated with vehicle (n = 10) or teduglutide (n = 11). The P value was calculated using the unpaired, 2-sided Student t test. (I) Relative Chga gene expression in the small intestine of allo-HCT BALB/c mice on day 10, treated with vehicle or teduglutide (n = 8 per group). Data are derived from 2 independent experiments. The P value was calculated using the unpaired, 2-sided Student t test. (J) Glp-2r gene expression from microarray-based analysis from BALB/c mice on day 10 treated with vehicle (n = 3) or teduglutide (n = 2) from day −3 until day +10. Results indicate an increase Glp-2r gene expression in teduglutide-treated mice compared with vehicle-treated animals. The experiment was performed once. Adjusted P = .02.

Teduglutide treatment leads to improved survival and reduced histological scores in mice with acute SR-GVHD. (A) Percentage survival of C57BL/6 allo-HCT mice treated with teduglutide or vehicle (n = 17 per group). Mice were treated with teduglutide or vehicle from day −3 until day +3 unless differently specified. Results are derived from 3 independent experiments. P value was calculated using the Mantel-Cox test. (B) GVHD histopathological scores from target organs of allo-HCT C57BL/6 animals on day 10, mice were treated with teduglutide or vehicle (n = 7 per group). Results are derived from 1 experiment. The P values were calculated using a 2-sided Mann-Whitney U test. (C) Percentage survival of allo-HCT BALB/c mice treated with teduglutide or vehicle (n = 12 per group). Results are derived from 2 independent experiments. P value was calculated using the Mantel-Cox test. (D) GVHD histopathological scores from small and large intestine and liver from allo-HCT BALB/c mice on day 10, animals were treated with teduglutide or vehicle (n = 8 per group). Results are derived from 2 independent experiments. The P values were calculated using a 2-sided Mann-Whitney U test. (E) Percentage survival of allo-HCT BALB/c mice treated with vehicle or teduglutide from day −3 to day 3 + prednisolone from day 4 to day 13 (n = 10 per group). Data are derived from 2 independent experiments. P value was calculated using the Mantel-Cox test. (F) Histological GVHD scores from BALB/c mice on day 10, treated as the schedule above described with teduglutide + prednisolone or vehicle + prednisolone (n = 9 per group). Data are derived from 2 independent experiments. The P values were calculated using a 2-sided Mann-Whitney U test. (G) Percentage survival of syn-HCT BALB/c mice treated with teduglutide or vehicle (n = 5 per group). Results are derived from 1 experiment. P value was calculated using the Mantel-Cox test. (H) Relative Cldn4 gene expression in the small intestine of allo-HCT BALB/c mice on day 5, treated with vehicle (n = 10) or teduglutide (n = 11). The P value was calculated using the unpaired, 2-sided Student t test. (I) Relative Chga gene expression in the small intestine of allo-HCT BALB/c mice on day 10, treated with vehicle or teduglutide (n = 8 per group). Data are derived from 2 independent experiments. The P value was calculated using the unpaired, 2-sided Student t test. (J) Glp-2r gene expression from microarray-based analysis from BALB/c mice on day 10 treated with vehicle (n = 3) or teduglutide (n = 2) from day −3 until day +10. Results indicate an increase Glp-2r gene expression in teduglutide-treated mice compared with vehicle-treated animals. The experiment was performed once. Adjusted P = .02.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal